Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

VALganciclovir vs. LETermovir for Primary Prevention of CMV in Moderate to High-Risk Heart Transplant Recipients (The VALET-CMV Study)

NCT07079735 is registered in ClinicalTrials.gov with Columbia University as lead sponsor.

NCT NCT07079735
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07079735 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
VALganciclovir vs. LETermovir for Primary Prevention of CMV in Moderate to High-Risk Heart Transplant Recipients (The VALET-CMV Study)
Lead sponsor
Columbia University
Phase
Phase 2/3
Overall status
Recruiting
Start date
September 12, 2025
Completion date
January 17, 2029
Enrollment
150 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cmv viremia, heart transplant failure and rejection, heart transplant infection